PT100279A - Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega - Google Patents

Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega

Info

Publication number
PT100279A
PT100279A PT100279A PT10027992A PT100279A PT 100279 A PT100279 A PT 100279A PT 100279 A PT100279 A PT 100279A PT 10027992 A PT10027992 A PT 10027992A PT 100279 A PT100279 A PT 100279A
Authority
PT
Portugal
Prior art keywords
treatment
perturbacoes
diphenylbutilpiperazinocarboxamides
usefulness
employs
Prior art date
Application number
PT100279A
Other languages
English (en)
Other versions
PT100279B (pt
Inventor
Anders Bjork
Erik Christensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of PT100279A publication Critical patent/PT100279A/pt
Publication of PT100279B publication Critical patent/PT100279B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT100279A 1991-03-22 1992-03-23 Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega PT100279B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use

Publications (2)

Publication Number Publication Date
PT100279A true PT100279A (pt) 1993-07-30
PT100279B PT100279B (pt) 1999-06-30

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100279A PT100279B (pt) 1991-03-22 1992-03-23 Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega

Country Status (24)

Country Link
US (2) US5434156A (pt)
EP (1) EP0538422B1 (pt)
JP (1) JP3221611B2 (pt)
KR (1) KR100196674B1 (pt)
AT (1) ATE199057T1 (pt)
AU (1) AU653797B2 (pt)
BG (1) BG61829B1 (pt)
BR (1) BR9204969A (pt)
CA (1) CA2083505C (pt)
CZ (1) CZ282222B6 (pt)
DE (1) DE69231680T2 (pt)
DK (1) DK0538422T3 (pt)
EE (1) EE02973B1 (pt)
ES (1) ES2154261T3 (pt)
GR (1) GR3035805T3 (pt)
HU (2) HU9203632D0 (pt)
IE (1) IE920920A1 (pt)
NO (1) NO301311B1 (pt)
PT (1) PT100279B (pt)
RO (1) RO109702B1 (pt)
RU (1) RU2095062C1 (pt)
SE (1) SE9100860D0 (pt)
SK (1) SK279237B6 (pt)
WO (1) WO1992016211A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
NZ539400A (en) * 2001-01-17 2006-04-28 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependence
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
AR062320A1 (es) 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
WO1992016211A1 (en) 1992-10-01
ATE199057T1 (de) 2001-02-15
PT100279B (pt) 1999-06-30
CZ344992A3 (en) 1994-02-16
CZ282222B6 (cs) 1997-06-11
BG61829B1 (bg) 1998-07-31
JP3221611B2 (ja) 2001-10-22
SK344992A3 (en) 1995-11-08
HU9203632D0 (en) 1993-03-29
GR3035805T3 (en) 2001-07-31
NO301311B1 (no) 1997-10-13
RO109702B1 (ro) 1995-05-30
AU1428092A (en) 1992-10-21
BR9204969A (pt) 1993-07-27
AU653797B2 (en) 1994-10-13
ES2154261T3 (es) 2001-04-01
NO924502D0 (no) 1992-11-23
SE9100860D0 (sv) 1991-03-22
HU217833B (hu) 2000-04-28
RU2095062C1 (ru) 1997-11-10
CA2083505C (en) 2003-06-10
NO924502L (no) 1992-11-23
IE920920A1 (en) 1992-09-23
US5618817A (en) 1997-04-08
SK279237B6 (sk) 1998-08-05
CA2083505A1 (en) 1992-09-23
EP0538422B1 (en) 2001-02-07
JPH05507731A (ja) 1993-11-04
DE69231680D1 (de) 2001-03-15
BG97108A (bg) 1994-03-24
KR100196674B1 (ko) 1999-06-15
EE02973B1 (et) 1997-04-15
DE69231680T2 (de) 2001-06-07
DK0538422T3 (da) 2001-05-07
KR930700108A (ko) 1993-03-13
HUT64696A (en) 1994-02-28
US5434156A (en) 1995-07-18
EP0538422A1 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
PT100279A (pt) Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
BR9907770A (pt) Mistura sinérgica de produtos naturais e seu uso
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
NO20010627D0 (no) Anvendelse av Gingko Biloba ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sclerose
ES2113549T3 (es) Metodo para inhibir la replicacion de vih empleando il-4.
GB8928609D0 (en) Pharmaceutical composition
KR920002150A (ko) 항말라리아 약학적 배합제
KR880012231A (ko) 스테로이드의 용도
KR940003550A (ko) 노인성 치매 예방 및 치료방법

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930322

FG3A Patent granted, date of granting

Effective date: 19990326

PC3A Transfer or assignment

Free format text: 20011210 PHARMACIA AKTIEBOLAG SE

PD3A Change of proprietorship

Owner name: PHARMACIA AKTIEBOLAG

Effective date: 20011210

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20060926